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Abstract 31 
For over 60 years, hematopoietic stem cell transplantation (HSCT) has been the major curative 32 
therapy for several hematological and genetic disorders, but its efficacy is limited by the secondary 33 
disease called graft versus host disease (GvHD). Huge advances have been made in successful 34 
transplantation in order to improve patient quality of life and yet, complete success is hard to 35 
achieve. This review assimilates recent updates on pathophysiology of GvHD, prophylaxis and 36 
treatment of GvHD related complications and advances in the potential treatment of GvHD. 37 
1. Introduction to Graft versus Host Disease (GvHD) 38 
GvHD is the most recognized complication post HSCT and was first observed in 1956 in a murine 39 
model. Barnes et al demonstrated that when irradiated mice were infused with allogenic marrow 40 
and spleen cells, mice recovered from radiation injury and aplasia but they developed diarrhea, 41 
weight loss, skin changes and liver abnormalities, and subsequently died due to “secondary 42 
disease”[1]. This phenomenon was recognized as GvHD. A decade later, in 1966, Billingham 43 
postulated three crucial requirements for the development of GvHD: 44 
 i) the transplanted graft must contain immunologically competent cells, 45 
 ii) the recipient must be incapable of rejecting or eliminating transplanted cells, 46 
iii) the recipient must express tissue antigens that are not present in the transplant donor, thus 47 
the recipient antigens are recognized as foreign by donor cells [2].  48 
Today, we know that the immunocompetent cells are T lymphocytes that are present in the stem 49 
cell inoculum and are required to mount an effective immune response [3]. A normal immune 50 
system is able to reject T cells from a foreign donor. However, when recipient’s immune system 51 
is compromised through the use of various immune-ablative agents (chemotherapy and/or 52 
radiotherapy), the recipient is incapable of rejecting the transplanted cells. We now know that the 53 
tissue antigens that differ in donor and recipient are major and minor human leukocyte antigens 54 
(HLA), and their expression on cell surfaces are crucial for the activation of allogenic T cells and 55 
initiation of GvHD (4). Previously it was believed that acute GvHD occurs within day 100 after 56 
transplantation and chronic GvHD occurs beyond day 100 and that the most affected organs at the 57 
onset of GvHD is skin (81%), gastrointestinal tract (54%) and liver (50%) [4]. Now it is clear that 58 
acute GvHD can occur after day 100 as late acute GvHD (e.g. after cessation of 59 
immunosuppression or after donor lymphocyte infusion (DLI)) or cause overlap syndrome of both 60 
acute and chronic GvHD [5].  61 
2. Pathophysiology of acute GvHD: a three-step model explaining the current strategies of 62 
prophylaxis and treatment 63 
Acute GvHD has been attributed to three stages. Initially there is tissue damage due to conditioning 64 
which in turn activates the host antigen presenting cells (APCs). Secondly, APCs activate donor T 65 
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cells, also known as an afferent phase. Finally, in efferent phase, cellular and inflammatory factors 66 
work together to damage the target organs.  67 
a. conditioning mediated tissue damage: conditioning is crucial to eradicate underlying disease 68 
and to support engraftment of donor cells without rejection by recipient[6]. Prior to donor cell 69 
infusion, patient’s tissues have been profoundly damaged due to underlying disease itself, 70 
treatment for the disease, infections, and the conditioning regimen [7, 8]. As a consequence, 71 
damaged host tissue release danger signals which include pro-inflammatory cytokines such as 72 
tumor necrosis factor (TNF) and interleukin-1 (IL-1) [9], that activate host APCs, ultimately 73 
activating donor T cells present in the stem cell inoculum [10, 11]. Conditioning mediated 74 
damage to the GI tract remains the main concern as GI tract allows systemic translocation of 75 
microbial products like lipopolysaccharide (LPS) and other pathogen associated molecular 76 
patterns (PAMPs) that greatly amplify host APC activation [8], leading to amplified T cell 77 
activation. Conditioning related damage also explains why the concept of reduced intensity or 78 
even non-myeloablative conditioning has contributed to less toxicity, less severe GvHD and 79 
reduced treatment related mortality. Some studies showed that delaying the transfer of donor 80 
cells after conditioning decreased the risk of GvHD [9, 12].  81 
b. donor T cell activation (the afferent phase): GvHD occurs when donor T cells activate and 82 
respond to HLA differences on recipient’s tissue [13]. Experimental models have proved that 83 
the host APCs are necessary and sufficient to activate donor T cells and initiate GvHD [11, 84 
14]. Donor T cells can recognize alloantigen either on host APC, known as direct antigen 85 
presentation [15] or on donor APCs, known as indirect presentation [16]. T cell responses 86 
depend on the disparity between the donor and the recipient with regard to HLA [13]. CD4+ 87 
T cells respond to the variations in MHC class II molecule (HLA-DR, DQ, DP) and CD8+ T 88 
cells respond to the variations in MHC class I molecule (HLA-A, B, C) [17]. Transplants 89 
carried out in the HLA matched sibling or identical twin setting can still give rise to GvHD 90 
due to differences in minor HLA [18]. The first to be described were HA-1 [19] and HA2 [20] 91 
and the subsequent clinical impact of minor histocompatibility antigens including H-Y 92 
antigens [21, 22] of female to male transplants has recently been reviewed [23, 24]. Minor 93 
HLAs are T cell epitopes which are originally derived from polymorphic or normal tissue 94 
proteins. These antigenic peptides can be presented on HLA Class I or Class II molecules and 95 
to date over 50 minor HLA antigens have been identified [24]. Minor HLA antigens have been 96 
associated with GvHD and graft versus leukemia (GvL) effects due to their tissue distribution. 97 
Minor HLA antigens restricted to the hematopoietic system may be able to enhance GvL 98 
responses while more broadly expressed minor HLA antigens contribute to both GvHD and 99 
GvL [25]. As well as cytotoxic T cell responses allogeneic H-Y antibodies have shown to 100 
predict chronic GvHD and non-relapse mortality [26, 27].  101 
T cell activation is in the focus of current immunosuppressive strategies used for prophylaxis 102 
and treatment. Calcineurin inihibitors, mycophenolate and mToR inhibitors interfere with 103 
different signals of T cell activation [28, 29]. The broader strategy is T cell depletion, which is 104 
currently applied by in vivo approaches such as the use of anti-thymocyte globuline 105 
pretransplant [30]. Cytotoxic approaches more or less selectively eliminates activated T cells 106 
if applied posttransplant; the old approach of methotrexate prophylaxis but also the more recent 107 
approach of using posttransplant cyclophosphamide engage this principle [31].  108 
 109 
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c. target cell apoptosis (the efferent phase): in this phase, both innate and adaptive immune 110 
cells work synergistically to exacerbate the T cell induced inflammation. Cellular mediators 111 
such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells utilize the Fas/Fas ligand 112 
(FasL) pathway and perforin/granzyme pathway to lyse the target cells [32, 33]. Furthermore, 113 
inflammatory cytokines synergize with CTLs, resulting in further tissue injury and possible 114 
target organ dysfunction [13]. In addition, microbial products like LPS, released during 115 
conditioning, leak through a damaged intestinal mucosa and skin, and stimulate mononuclear 116 
cells (monocytes/macrophages) to secret inflammatory cytokines leading to amplification and 117 
propagation of a cytokine storm [13]. This leads to destruction of epithelial cells, mostly in the 118 
GI tract.  119 
The broad activity of corticosteroids including induction of T cell apoptosis, suppression of 120 
macrophage activation and cytokine release explains why these old drugs are still the treatment 121 
of choice for first line treatment of both acute and chronic GvHD. Cytokine inhibitors like TNF 122 
blocking agents were thought to be more specific but did not result in increased response rates 123 
[34]. For almost all second line strategies in steroid-refractory acute GvHD low response rates 124 
associated with high treatment related mortality have been reported indicated the urgent need 125 
for further improvement [35]. 126 
In the last 10 years, the concept of GvHD pathophysiology has been largely extended and a more 127 
differentiated view has been adapted. 128 
Firstly, the mechanism of conditioning related damage has further been specified. It is now clear 129 
that the tissue damage results in release of several danger signals such as uric acid and the 130 
metabolites of ATP pathway and its receptor have been shown to be involved in activation of 131 
GvHD [36]. 132 
Secondly, the concept of LPS triggered inflammation has been substituted by multiple microbiota 133 
derived signals and differential activation of Toll-like receptors (TLRs) and Nod-like receptors 134 
(NLRs). NOD2/CARD15 has been shown to be involved in triggering the inflammation both in 135 
mice [37, 38] and men [39]. More recently it became clear that the microbiota of epithelial tissues 136 
is a the major player influencing epithelial integrity and local immune tolerance by commensal 137 
bacteria and millions of metabolites are produced to maintain epithelial homeostasis [40, 41]. 138 
Finally, and in context with the concept of microbiota as important players, the importance of 139 
regulatory immune cells which balance immune reactions is recognized. Regulatory T cells (Tregs) 140 
expressing the transcription factor Foxp3 occur as natural, thymus derived T cells and are able to 141 
prevent alloreaction [42]. On epithelial surfaces, induced peripheral Tregs try to dampen acute 142 
inflammation [43]. Foxp3 positive T cells act in cooperation with numerous newly identified 143 
regulatory populations such as invariant natural killer T (iNKT) cells [44], myeloid derived 144 
suppressor cells (MDSCs) and a whole new set of innate immune cells such as innate lymphoid 145 
cells (ILCs) [45]. Figure 1 represents the GvHD initiation phase. Figure 2 summarizes the 146 
complete pathophysiology of aGvHD. 147 
3. In vitro Modelling of GvHD to give insight into the pathophsiology  148 
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The skin explant model has long been established as a tool for studying the immunobiology of 149 
GvHD and more recently has been used to investigate the specificity of anti-viral T cells in graft 150 
versus host reactions ( 34, 35, 36) the role of Tregs and mechanisms of apoptosis [46, 47].  151 
The skin explant model has also been used to assess the safety of ex vivo expanded Treg cells as 152 
well as their capacity to prevent graft versus host (GvH) reactions [48]. Activated and expanded 153 
polyclonal Treg, at any cell concentration, did not induce any significant GvH reactions. 154 
Over recent years significant advances in the understanding of the benefits of Tregs in 155 
hematopoietic stem cells transplantation have resulted in the completion of early stage clinical 156 
trials as well as the initiation of trials in solid organ transplantation [49-52]. These early stage 157 
HSCT trials have provided promising results showing a reduction the incidence of GvHD without 158 
adversely effecting relapse, transplant related mortality and engraftment. Using the skin explant 159 
model it has been possible to investigate the cellular and molecular mechanisms by which Treg 160 
are likely to be preventing GvHD following HSCT.  161 
We have shown that for Treg to suppress GvH reactions they need to be present during the priming 162 
of allo-reactive T cells [48]. Polyclonal Treg cells were expanded ex vivo and added into the skin 163 
explant model at either the priming or the effector stage. The later addition of Treg, during the 164 
effector phase, impaired their suppressive capacity. This suggests that Treg may be more effective 165 
when given early, as prophylaxis, rather than as a treatment. This study also demonstrated that in 166 
humans an effector to Treg ratio of 4:1 was sufficient to modulate GvH reactions, whereas previous 167 
studies in mice had suggested a 1:1 ratio was necessary. This study has therefore provided 168 
preclinical evidence to support the safety and feasibility of ex vivo expanded Treg as a novel 169 
therapeutic and provides information on the optimal timing and dose of Treg to prevent GvH 170 
reactions.  171 
Further work using the skin explant model has been able to elucidate some of the mechanisms by 172 
which Treg are able to prevent GvHR. The presence of Treg during the priming of allo-reactive T 173 
cells reduced their cytotoxic capacity [48]. Further investigations showed Treg also impaired the 174 
ability of allo-reactive T cells to migrate into the target tissues [53]. The presence of Treg during 175 
priming resulted in a reduction in IFNγ production by CD8+ cytotoxic T cells, as well as a reducing 176 
expression of skin homing molecules CXCR3 and CLA. This paired with a reduction in levels of 177 
the chemokines CXCL10 and CXCL11 in the skin resulted in a significant reduction in the number 178 
of cytotoxic T cells present in the skin and decreased the GvH severity. We have since 179 
demonstrated that Treg are able to modulate GvH reactions through impairment of dendritic cells 180 
at a transcriptional level, arresting them in a semi-mature status and leaving them functionally 181 
impaired [54] 182 
The skin explant model has also been used to investigate the involvement of epithelial FAS in the 183 
pathophysiology of GvHD [55]. Animal models have previously shown the critical role for 184 
FAS/FASL in GvHD [56]. Ruffin et al showed that there was a significant increase in FAS 185 
expressing cells in GvHR positive experiments and that FAS mediated apoptosis was involved in 186 
the induction of GvHR, as blocking FAS mediated apoptosis reduced the severity of GvHR. They 187 
also showed that levels of FAS in the serum of patients who received myeloablative conditioning 188 
was increased, possibly due to the higher toxicity. This supports the potential use of FAS as a 189 
therapeutic target. 190 
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4. Identification of Biomarkers 191 
As well as investigating the safety of cellular therapies and immunology of GvHD, the skin explant 192 
model has been used in recent years to identify biomarkers. Within our group we used the skin 193 
explant model to validate a number of biomarkers which had been identified in the serum of HSCT 194 
patients [57]. BAFF and IL-33 levels were elevated pre-transplant in patients who then went on to 195 
develop aGvHD, and therefore could have the potential to act as predictive biomarkers. We also 196 
found that CXCL10 and CXCL11 were suitable as diagnostic markers of GvHD. Training and 197 
validation cohorts were used to highlight the association of these potential biomarkers to GvHD. 198 
Then the skin explant model was used to confirm their association with GvH reactions. 199 
Immunohistochemistry was carried out on sections from the skin explant and increased staining 200 
for BAFF, IL-33, CXCL10 and CXCL11 was seen in skin explants with a higher grade GVHR. 201 
This was further confirmed in clinical biopsies demonstrating increased levels of protein, measured 202 
with immunohistochemistry and gene expression for BAFF, CXCL10 and CXCL11. In this study 203 
the skin explant proved to be a useful tool in validating a panel of biomarkers which had been 204 
identified in patient samples. The skin explant is not exclusive to the human setting. Recently 205 
Zinocker et al have described the use of a rat skin explant model for investigating the 206 
pathophysiology of GvHD [58] as well as gene expression profiling [59].  207 
Harris et al [60] have recently reviewed the use of biomarkers in predicting acute GvHD which 208 
include genomic factors as well as plasma proteins. One of the first studies demonstrated that a 209 
panel of tumor necrosis factor receptor –type 1 (TNFR1) interleukin -2 receptor alpha (IL-2 α), 210 
IL-8 and hepatocyte growth factor (HGF) had prognostic as well as diagnostic value in predicting 211 
acute GvHD [61]. Other markers in the skin such as elafin [61] and plasma biomarkers of the lower 212 
GI tract and liver acute GvHD have been validated in subsequent studies and the most significant 213 
of these was regenerating islet-derived 3 alpha (Reg3a) [62, 63]. These studies led to the use of 214 
the biomarkers TNFR1, ILRα, IL-8, HGF, Reg3α and elafin for measuring responsiveness to 215 
GvHD therapy. The panel was able to predict 28 day post therapy non response and day 180- 216 
mortality in a cohort of 112 patients [64]. 217 
 In addition an algorithm using concentrations of three biomarkers-TNFR1, soluble IL-33 receptor 218 
[ST2] and Reg3α, Levine and colleagues [65] were able to calculate the probability of nonrelapse 219 
mortality caused by non-responsive GVHD and divide the patients into distinct groups to predict 220 
response to GVHD therapy. The researchers subsequently developed the Mount Sinai Acute 221 
GVHD International Consortium (MAGIC), which consists of a group of 10 trannsplant centers in 222 
the United States and Europe who collaborate on the use of this scoring system to test new 223 
treatments for acute GVHD.  224 
5. Pathophysiology of chronic GvHD 225 
Although the pathophysiology of chronic GvHD (cGvHD) is poorly understood, it remains the 226 
major cause of late non-relapse death after HSCT [66]. cGvHD may manifest simultaneously from 227 
aGvHD, develop after the treatment of aGvHD or may occur de novo [67]. Classical cGvHD 228 
occurs 100 days after transplantation but may also overlap with aGvHD [5, 68].  229 
Acute GvHD is a major risk factor of cGvHD and strategies aiming at T cell depletion at the time 230 
of transplantation to prevent cGvHD demonstrate that early events impact on the development of 231 
cGvHD. As immune cells and immune organs such as thymus, bone marrow niche and spleen are 232 
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the primary targets of acute GvHD, thymus destruction and deficient selection of donor T cells by 233 
the thymus are the major factors resulting in allo- and autoimmunity associated with chronic 234 
GvHD [69] . Due to early damage of the B cell niche in the bone marrow, B cell development is 235 
strongly disturbed resulting in elevated BAFF levels as a predictor of chronic GvHD and 236 
insufficient elimination in B cells producing auto- and alloantibodies [70]. A hallmark of cGvHD 237 
is development of sclerotic lesions which can occur in almost every organ [68]. While previous 238 
data favors a concept of defective wound healing with increase production of sclerotic cytokines 239 
such as TGFβ and PDGF, recent evidence supports a role of specific TH17 subsets in this sclerotic 240 
process [71].  241 
6. Target organ damage during GvHD 242 
Skin is the principal target organ of GvHD and the initial manifestation in the skin is 243 
maculopapular rash which has the potential to spread throughout the body [13]. The rash may 244 
resemble folliculitis or may resemble sunburn. In extreme cases, skin may blister and ulcerate [13, 245 
72]. Acute cutaneous GvHD usually begins with erythematous, rashes on the ears, palms and soles. 246 
Martin and coworkers reported results of 740 allogenic transplantations and 81% of patients with 247 
aGvHD had skin involvement [4]. Damage to the skin could be defined by vacuolar degeneration 248 
of the basal cell layer, dyskeratotic keratinocytes and mononuclear cell infiltrates [73]. Epithelial 249 
damage occurs at the tips of rete ridges and hair follicles, regions where selective targeted apoptotic 250 
rete cells are located [74]. A recent study by Paczesny et al reported that elafin could be a potential 251 
biomarker for diagnosis and prognosis of skin GvHD [75].  252 
Liver is another target organ of GvHD. Hepatic GvHD is manifested by abnormal liver function 253 
tests and a rise in the serum level of bilirubin and alkaline phosphatase. Donor lymphocytes attack 254 
the bile duct epithelial cells causing endothelialitis, pericholangitis and apoptotic bile duct 255 
destruction [76]. While liver GvHD affecting bile ducts and resulting in severe hyperbilirubinemia 256 
occurs less frequently, there is an increasing rate of hepatitis like cGvHD as another, but less 257 
harmful liver lesion [77].  258 
Gastro-intestinal (GI) tract represents the most severely affected organ after conditioning. GI 259 
GvHD is characterized by secretory and voluminous diarrhea, severe abdominal pain, vomiting 260 
and anorexia [13]. Snover and colleagues used immunohistochemistry to explain histologic 261 
features of the GI tract during GvHD [78]. Single cell apoptosis was observed along with patchy 262 
ulcerations and apoptotic bodies in the base of crypts with loss of the surface epithelium [13, 78]. 263 
The base of the intestinal crypts, where epithelial stem cells are located, is the most sensitive target 264 
for GvHD as it is the site of epithelium regeneration and Paneth cells. Recently, Levine and 265 
colleagues observed loss of the Paneth cells at the onset of GI GvHD [79] suggesting these cells 266 
as sensitive targets of GvHD. In addition, as stated earlier , it was proposed that regenerating islet-267 
derived 3-a (reg3a), released from Paneth cells, was a potential plasma biomarker for lower GI 268 
GvHD [63], Paneth cell damage contributes to loss of antimicrobial peptides and accelerates the 269 
loss of microbial diversity in GvHD , a major risk factor of treatment related mortality [80, 81].  270 
7. Further HSCT related complications 271 
7.1 Overview 272 
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Although GvHD is the main complication of allogeneic SCT, non-relapse related mortality (NRM) 273 
can occur independently from the occurrence of GvHD or in patients with minor GvHD. Overall, 274 
NRM has decreased in the last 10 years as a result of several improvements such as reduced 275 
intensity conditioning; resulting in reduced organ toxicity, improved donor selection and matching, 276 
and progress in supportive treatment [82]. 277 
Major complications include viral and fungal infections, which can occur independently from 278 
GvHD due to the immunodeficiencies induced by HSCT. GvHD and its treatment aggravate and 279 
prolong the risk of infectious complications, and many patients suffering from severe GvHD die 280 
from infectious complications. Beyond the period of acute GvHD, chronic GvHD and long term 281 
complications are major causes of NRM and morbidity. Long term complications include organ 282 
toxicities, endocrine deficiencies and most important secondary cancers. HSCT patients survivors 283 
therefore need a long term follow up in order to allow early detection of complications and several 284 
guidelines summarize the current recommendations [83, 84]. 285 
A detailed presentation of infectious complications, organ toxicities and long term complications 286 
is beyond the focus of this review, we therefore focus on the most relevant targets of complications: 287 
endothelial cells and pulmonary complications. 288 
7.2 Endothelial complications 289 
Endothelial complications occur clinically throughout the different phases of HSCT. In the early 290 
weeks after transplantation, sinusoidal obstruction syndrome (SOS) formally known as veno-291 
occlusive disease (VOD) can result in severe liver damage and eventually multi-organ failure [85, 292 
86]. SOS results from conditioning related toxicity in the sinusoids of the liver with subsequent 293 
occlusions by thrombosis and fibrosis. In the period of engraftment, cytokine storm mediated 294 
capillary leakage syndrome can occur. With the introduction of calcineurin-inhibitors (CNI) for 295 
prophylaxis of GvHD, which also give rise to some endothelial toxicity, transplant associated 296 
microangiopathy (TAM) has been increasingly observed during acute GvHD [87]. Manifestations 297 
of intestinal TAM can mimic severe GvHD and provoke intestinal bleeding but requires a different 298 
treatment regimen. Besides CNI associated TAM, it can also occur as atypical hemolytic uremic 299 
syndrome (HUS) which results from a failure of cleaving von Willebrand Factor [88, 89]. In long 300 
term patients cerebro- and cardiovascular complications are increased. 301 
While clinical endothelial complications have been well known for many years, more recently the 302 
pathophysiology of endothelial cells in GvHD has been studied. In vitro models of endothelial cell 303 
cultures reveal that conditioning can induce endothelial apoptosis, which is aggravated by LPS 304 
mediated inflammation and followed allogeneic cytotoxic T cell damage [90]. Murine models have 305 
demonstrated the role of endothelial neovascularization induced by conditioning leading to GvHD 306 
[91-93] and infiltrating donor T cells. Recently, Schmid et al showed for the first time in a murine 307 
system, that not only endothelial venules but also arterial vessels suffer direct endothelial damage 308 
during GvHD [94]. Detailed studies in patients have shown an association of loss of dermal 309 
vessels, with CD8+ T cell infiltrates, demonstrating allogeneic reactions against endothelial cells 310 
[95, 96]. More recently, endothelial damage has been shown to contribute to steroid resistance and 311 
failure to recover from GvHD. Loss of protective thrombomodulin was observed in biopsies from 312 
GvHD patients [97] together with increased serum thrombomodulin [98]. In addition, genetic 313 
SNPs within the thrombomoduline gene have been identified as risk factors for GvHD [99]. 314 
Finally, circulating endothelial factors such as angiopoietin levels pre transplant and VEGF levels 315 
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post-transplant have been identified as risk factors of GvHD [100] which paves the way for 316 
infiltrating donor T cells.  317 
7.3 Pulmonary complications 318 
A further central target organ of HSCT related complications is the lung. Early after 319 
transplantation, bacterial and fungal pneumonia are common, mainly due to aspergillus 320 
predomination. In the post-transplant period of GvHD and immune reconstitution, viral pneumonia 321 
caused by CMV, respiratory viruses (Influenza, Parainfluenza, RSV, Metapneuomovirus) and 322 
adenoviruses predominate as well as fungal pneumonia, especially in patients with severe 323 
immunosuppression [101]. In addition, further infectious agents such as toxoplasma gondii and 324 
pneumocystis jirovecii causing toxoplasma and pneumocystis pneumonia ( PcP ) respectively, can 325 
cause pneumonia during the period of B cell reconstitution while B cell numbers are absent or low. 326 
Pneumonias caused by encapsulated bacteria such as pneumococci are also observed [102, 103]. 327 
Early after HSCT, peri-engraftment respiratory distress syndrome (PERDS) causes rapid 328 
deterioration of respiratory functions during leukocyte recovery, but responds rapidly to high dose 329 
corticosteroid treatment. In the initial stages of aGvHD, idiopathic pneumonia syndrome (IPS) is 330 
a serious complication resulting from conditioning related toxicity and LPS triggered allogeneic 331 
reactions. IPS may or may not be exacerbated by occult or unknown infections [89] and in either 332 
case, TNF blocking agents have been shown to be effective in both experimental models and in 333 
patients [86-88]. The most frequent complication is bronchiolitis obliterans syndrome (BOS) 334 
characterized by inflammation of the small bronchiole with subsequent obstruction and lung 335 
destruction [104, 105]. Early monitoring and intervention with topical corticosteroids, 336 
azithromycin and possibly systemic immunosuppression is needed to prevent progression to 337 
irreversible lung damage which may lead a requirement for lung transplantation [106, 107]. 338 
Besides BOS, restrictive changes can be observed such as pulmonary fibrosis, BOOP 339 
(bronchiolitis obliterans organizing pneumonia) and pulmonary veno-occlusive disease [108].  340 
Cellular therapy is one approach increasingly used as a second line treatment. Tregs [109] and 341 
MSCs [110-112] are promising cellular products, but phase 3 trials are yet to be conducted.  342 
8. Recent advances and perspectives in GvHD 343 
For over 30 years, immunosuppressive drugs have served as a central strategy to reduce GvHD. 344 
Drugs such as sirolimus, tacrolimus and methotrexate are the main-stay in the treatment of GvHD 345 
[113]. Complete ex vivo T cell depletion is no longer routinely used in HLA matched 346 
transplantation as it also largely abolishes GvL effects. A more recent report from Finke and 347 
colleagues suggested ATG as an in vivo T cell depletion may be more efficacious in lowering the 348 
incidence of severe acute GvHD in matched and mismatched HSCT from unrelated donors while 349 
GvL effects seemed less affected [114]. 100 patients were enrolled in the study. Comparable 350 
outcomes were obtained for GvHD patients receiving bone marrow or peripheral blood stem cells 351 
from matched or one antigen mismatched unrelated donors when ATG was added to the standard 352 
prophylaxis (cyclosporine+methotrexate) [114]. The use of ATG may therefore contribute to 353 
balance GvH versus GvL effect and enable HLA mismatch donors to be used as well as fully match 354 
unrelated donors, with no difference in outcome. As an alternative, elimination of alloreactive T 355 
cells by post-transplant cyclophosphamide may become an option, which is already widely used 356 
for GvHD prophylaxis following haploidentical transplantation [115]. Whether this approach can 357 
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be integrated in the HLA identical setting as a potential alternative to calcineurin inhibitors is under 358 
current investigation. 359 
 360 
Pathogen recognition receptors (PRRs) like NLRs and TLRs are known to control adaptive 361 
immune responses in inflammatory disorders [37] and the research on the role of these receptors 362 
has resulted in the description of the interaction of the microbiota and the immune system in the 363 
setting of GvHD. Loss of microbiome diversity early after HSCT has been recognized as a new 364 
risk factor for GvHD and HSCT related complications [116]. This observation suggests that 365 
restoration of a diverse microbiome could be a new approach to induce intestinal and systemic 366 
tolerance, and pre-/pro- and post biotic strategies, as well as several approaches of fecal microbiota 367 
transplantation (FMT) which are currently being tested in both experimental and clinical settings 368 
of HSCT [41]. 369 
Tregs have been expanded in vitro and used for prophylaxis and treatment of GvHD in 370 
experimental and small clinical trials [117, 118]. Another option is induction of Tregs in patients 371 
e.g. by Interleukin-2 (IL-2) [119]. Induction of Tregs has also been postulated as one mechanism 372 
explaining the beneficial action of extracorporeal photopheresis for treatment of acute and chronic 373 
GvHD [120, 121]. Besides Tregs, numerous alternative candidates for cellular therapy of GvHD 374 
exist such as MDSCs [122]. MSCs are indirect immunoregulatory cells which induce tissue repair 375 
and show some promising activity in steroid refractory GvHD [123, 124].  376 
Among pharmacological agents, drugs with anti-inflammatory effects of corticosteroids but 377 
without numerous side effects are urgently needed. Recently, anti-inflammatory JAK2 inhibitors 378 
have shown promising effects both in GvHD and in rheumatology. Proteasome inhibitors and 379 
histone deacetylase (HDAC) inhibitors originally developed as anticancer drugs now show some 380 
promising activity in dampening T cell responses [125]. In cGvHD, the role of aberrant B cells is 381 
increasingly recognized which paves the way for anti-B cell strategies like rituximab or new B cell 382 
development inhibitors like the Bruton’s tyrosine kinase (BTK)-inhibitor ibrutinib [70] 383 
A major issue in the treatment of aGvHD is that most approaches are initiated too late, when major 384 
changes have already severely damaged the target tissue. Therefore, biomarkers allowing early 385 
identification of patients at high risk are needed. A handful of biomarkers have been discovered 386 
which might be used to guide treatment in the future [65].  387 
Finally, the practice of stem cell transplantation differs between countries, within the same 388 
countries and between transplantation institutes. Approaches aimed at standardization of diagnosis 389 
and treatment are urgently needed, some of which have been addressed by several consensus 390 
projects [68, 126].  391 
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Figure legends 763 
Figure 1. Initiation of GvHD. Conditioning regimen leads to destruction of epithelial cells 764 
and their integrity. Damaged epithelia secrete uric acid and adenosine triphosphate (ATP) that 765 
results in production of pro-inflammatory cytokines. Pathogen recognition receptors (PRRs) 766 
such as Toll-like receptors (TLRs), NOD-like receptors (NLRs) and P2XRs are activated by 767 
pathogen associated molecular patterns (PAMPs) and danger associated molecular patterns 768 
(DAMPs). These signals ultimately activates antigen presenting cells (APCs) that leads to 769 
donor T cell activation. Adopted and modified from [37] 770 
Figure 2. Pathophysiology of acute GvHD. Conditioning regimen cause profound damage to 771 
the host tissues leading to release of inflammatory cytokines like TNF, IL-1. These cytokines 772 
activate host APCs in phase I. In addition, loss of microbial diversity and metabolites thereof 773 
leads to loss of epithelial and immune homeostasis. Host APCs activate mature donor T cells 774 
present in stem cell inoculum in phase II. T cells subsequently proliferate and differentiate into 775 
Th1 and Th17 type which are involved in activation of CD4 CTL, CD8 CTL and NK cells that 776 
mediate tissue damage. In phase III, effector T cells together with storm of pro-inflammatory 777 
cytokine attack the epithelial cells of skin, liver, lung and GI tract. This damage is further 778 
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supported by the LPS that has leaked through damaged intestinal mucosa which then recruit 779 
myeloid cell to further produce pro-inflammatory cytokines and thus enhances the cytokine 780 
storm. Adopted and modified from [13]. 781 
Figure 3. Skin explant grades I –IV 782 
The outcome of the skin explant assay is histopathological damage ranging from grade I 783 
GvHR (with minimal vacuolisation in the epidermis) to Grade II GvHR (with vacuolisation 784 
and dyskeratotic bodies) to Grade III GvHR (with sub epidermal cleft formation) and finally 785 
to Grade IV GvHR (with separation of the dermis from the epidermis). 786 
 787 
 788 
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